| Size | Price | |
|---|---|---|
| 1mg | ||
| 5mg | ||
| 10mg | ||
| 50mg | ||
| 100mg | ||
| Other Sizes |
| ln Vitro |
In renal tubular epithelial cells, 84-B10 (10-100 μM; 2 h) suppresses ferroptosis caused by cisplatin in a dose-dependent manner [1]. The mitochondrial structural damage and dysfunction caused by cisplatin are restored by 84-B10 (40 μM; 2 hours; TKPT cells) [1]. 84-B10 (40 μM; 2 hours; TKPT cells) attenuates oxidative stress caused by mtROS in cisplatin-induced acute kidney injury [1]. By removing mtROS and reestablishing mitochondrial homeostasis, 84-B10 (40 μM; 2 hours; TKPT cells) reduces the damage that cisplatin causes to epithelial cells [1].
|
|---|---|
| ln Vivo |
In mice, 84-B10 (5–15 mg/kg; ip) lessens acute renal damage caused by cisplatin [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: tubular epithelial cell Tested Concentrations: 10, 20, 30, 40, 50, and 100 μM Incubation Duration: 2 hrs (hours) Experimental Results: Increased the levels of NRF2, SLC7A11, and GPX4 in a dose-dependent manner. Western Blot Analysis[1] Cell Types: TKPT cells Tested Concentrations: 40 μM Incubation Duration: 2 hrs (hours) Experimental Results: Increased the levels of OM Porins, IMS Cyt c, IM CVa, IM Core 1, and Matrix CypD in a dose-dependent manner. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice with acute kidney injury[1]
Doses: 5, 10, and 15 mg/kg Route of Administration: intraperitoneal (ip)injection Experimental Results: diminished the sCr and BUN levels of cisplatin-exposed mice. Attenuated renal tubules morphological abnormalities in a dose-dependent manner. diminished NGAL and KIM-1 levels in a dose-dependent manner. diminished the transcription levels of Lcn2 (which encodes NGAL) and Havcr1 . |
| References |
| Molecular Formula |
C25H22F3NO5
|
|---|---|
| Molecular Weight |
473.441097736359
|
| Exact Mass |
473.145
|
| CAS # |
698346-43-9
|
| PubChem CID |
2812813
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
34
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N(C1C=C(C(F)(F)F)C=CC=1OC1C=CC(OC)=CC=1)C(=O)CC(C1C=CC=CC=1)CC(=O)O
|
| InChi Key |
UMUXAMJXLBOQNN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H22F3NO5/c1-33-19-8-10-20(11-9-19)34-22-12-7-18(25(26,27)28)15-21(22)29-23(30)13-17(14-24(31)32)16-5-3-2-4-6-16/h2-12,15,17H,13-14H2,1H3,(H,29,30)(H,31,32)
|
| Chemical Name |
5-[2-(4-methoxyphenoxy)-5-(trifluoromethyl)anilino]-5-oxo-3-phenylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (211.22 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (2.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1122 mL | 10.5610 mL | 21.1220 mL | |
| 5 mM | 0.4224 mL | 2.1122 mL | 4.2244 mL | |
| 10 mM | 0.2112 mL | 1.0561 mL | 2.1122 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
